Funded in October 2017, the family office focused on early-stage Biotech/Medtech investments primarily in Switzerland. The firm has accumulated over 40M CHF investment amount over the past 24 months. The firm’s biggest investment in a single company is CHF 5M thus far, but the size of investment could vary. The firm looks for companies located around the globe, with a preference in Switzerland or Europe. The firm is actively seeking new investment opportunities.
The firm looks to invest 70% in Therapeutics, 20% in Medical Devices, and 10% Digital Health/Others. In Therapeutic areas, the firm might invest half in early-stage and another half in later-stage. The firm is opportunistic in indications and willing to consider orphan indications. The firm seeks technologies that could fill unmet medical needs.
The firm has no specific requirements on companies. The firm currently acts as lead investors for two companies, and has represented in five boards. The firm might take a board seat depends on applicable cases.
If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.
Leave a Reply